Get the Stockscreener App
61.10
2.38%
-1.49
After Hours:
61.10
Hologic Inc stock is traded at $61.10, with a volume of 2.43M.
It is down -2.38% in the last 24 hours and down -3.82% over the past month.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
See More
Previous Close:
$62.59
Open:
$62.19
24h Volume:
2.43M
Relative Volume:
1.04
Market Cap:
$13.87B
Revenue:
$4.03B
Net Income/Loss:
$789.50M
P/E Ratio:
18.35
EPS:
3.33
Net Cash Flow:
$1.15B
1W Performance:
-1.58%
1M Performance:
-3.82%
6M Performance:
-24.02%
1Y Performance:
-19.22%
1-Day Range:
$60.63
$62.41
1-Week Range:
$60.63
$66.50
52-Week Range:
$60.63
$84.67
Hologic Inc Stock (HOLX) Company Profile
Name
Hologic Inc
Sector
Industry
Phone
(508) 263-2900
Address
250 CAMPUS DRIVE, MARLBOROUGH, MA
Compare HOLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
61.10 | 13.87B | 4.03B | 789.50M | 1.15B | 3.33 |
|
ISRG
Intuitive Surgical Inc
|
497.30 | 177.37B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
223.82 | 64.27B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
88.78 | 43.91B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
220.22 | 32.35B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
34.41 | 17.57B | 17.28B | 108.00M | 391.00M | 0.20 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-25 | Downgrade | Argus | Buy → Hold |
| Feb-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-03-25 | Downgrade | Needham | Buy → Hold |
| Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Dec-10-24 | Reiterated | Needham | Buy |
| Oct-01-24 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-24 | Initiated | Stephens | Overweight |
| Apr-03-24 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-23 | Upgrade | Needham | Hold → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jul-20-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-20-22 | Initiated | UBS | Neutral |
| Jul-18-22 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Oct-14-21 | Initiated | Redburn | Neutral |
| Jul-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-20-20 | Downgrade | Needham | Buy → Hold |
| Nov-05-20 | Reiterated | Needham | Buy |
| Jun-30-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-03-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-30-20 | Reiterated | Needham | Buy |
| Apr-30-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Apr-07-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-01-19 | Reiterated | Needham | Buy |
| May-02-19 | Reiterated | Needham | Buy |
| Jan-31-19 | Reiterated | Needham | Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-09-18 | Initiated | UBS | Neutral |
| Sep-13-18 | Downgrade | BofA/Merrill | Buy → Neutral |
View All
Hologic Inc Stock (HOLX) Latest News
Hologic stock hits 52-week low at $61.67 amid market shifts By Investing.com - Investing.com South Africa
Fluoroscopy Devices Market Set to Expand Due to Rising Demand - openPR
Clinical Diagnostic Market Set for Strong Growth | Advanced - openPR
Is Hologic, Inc. (NASDAQ:HOLX) Potentially Undervalued? - Simply Wall St
Breast Cancer Screening Market to Hit $11.7 Billion by 2033Key - openPR
Molecular Diagnostics Market Business Opportunities - openPR
Cancer Diagnostics Market Top PlayersGE Healthcare, Abbott - openPR
Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Mutual of America Capital Management LLC - Defense World
Why Is Hologic (HOLX) Down 4.5% Since Last Earnings Report? - Yahoo Finance
Lumos expands development deal with Hologic for premature birth test - MSN
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock - Yahoo Finance
Cosmetic Surgery Market Forecast Report and Company - GlobeNewswire
Cosmetic Surgery Market Forecast Report and Company Analysis 2025-2033 Featuring AbbVie, Cutera, Sientra, Bausch Health, Johnson & Johnson, Apyx Medical, Hologic, Merz Pharma, Galderma, Cynosure - Yahoo Finance
SVB Wealth LLC Makes New $949,000 Investment in Hologic, Inc. (NASDAQ:HOLX) - MarketBeat
Hologic, Inc. (NASDAQ:HOLX) Receives Consensus Rating of “Hold” from Brokerages - Defense World
Mammography Machine Market Expands: $2.6 Bn in 2024 to $4.1 Bn - openPR
X-ray Machine Manufacturing Market to Witness Remarkable - openPR
Digital X-ray Devices Market to Witness Remarkable Growth with Hologic, Inc., Hitachi, Ltd., Siemens Healthineers - openPR
Hologic (NASDAQ:HOLX) Price Target Cut to $70.00 by Analysts at Citigroup - Defense World
Fluoroscopy Devices Market Projected To Witness Massive - openPR
Hologic (NASDAQ:HOLX) Sets New 1-Year Low After Analyst Downgrade - Defense World
Hologic stock touches 52-week low at $62.67 amid market shifts - Investing.com Canada
Breast Cancer Brachytherapy Market Future Business - openPR
11 Analysts Have This To Say About Hologic - Benzinga
Hologic cut to Hold at Argus amid slower mammography equipment sales - Yahoo Finance
Lumos expands deal for premmie birth test - NT News
Citigroup Adjusts Price Target on Hologic to $70 From $80, Maintains Neutral Rating -March 04, 2025 at 06:07 am EST - Marketscreener.com
Breast Cancer Diagnostic Market Projected To Witness Massive - openPR
Hologic, Inc. (HOLX) Announces Retirement of General Counsel Joh - GuruFocus.com
In Vitro Diagnostic (IVD) Reagents Market Top PlayersMerck - openPR
Hologic Inc. announces executive transition By Investing.com - Investing.com Canada
Hologic Inc. announces executive transition - Investing.com
Hologic Announces Leadership Transition with New General Counsel - TipRanks
Argus Downgrades Hologic to Hold From Buy -March 03, 2025 at 08:21 am EST - Marketscreener.com
Lumos Diagnostics expands scope of work under Hologic fetal fibronectin development agreement - Proactive financial news
Lumos Diagnostics Expands Development Agreement with Hologic for Enhanced fFN Test - TipRanks
Here's What To Make Of Hologic's (NASDAQ:HOLX) Decelerating Rates Of Return - Yahoo Finance
Hologic, Inc. to Host Earnings Call - ACCESS Newswire
Hologic Faces Revenue Dip Following Demand Drop And Supply Challenges - Finimize
Investor Network: Hologic, Inc. to Host Earnings Call - ACCESS Newswire
New York State Common Retirement Fund Sells 9,000 Shares of Hologic, Inc. (NASDAQ:HOLX) - MarketBeat
UniCredit Iasi Open Returns to Hologic WTA Tour - WTA Tennis
Sanctuary Advisors LLC Lowers Stake in Hologic, Inc. (NASDAQ:HOLX) - Defense World
Principal Securities Inc. Lowers Stock Holdings in Hologic, Inc. (NASDAQ:HOLX) - Defense World
Hologic Wins Key Approvals Post Q1 Results: Buy or Hold HOLX Stock? - Nasdaq
Hologic, Inc. (NASDAQ:HOLX) Shares Bought by Illinois Municipal Retirement Fund - MarketBeat
Digital Breast Tomosynthesis Equipment Market Future Business - openPR
Hologic to Webcast Presentation at the Raymond James 46th Annual Institutional Investors Conference - Marketscreener.com
How to Watch Hologic's Strategic Presentation at Major Raymond James Investor Conference - StockTitan
Infectious Disease Diagnostics Market Generated - openPR
Womens Health Diagnostic Test Market Future Business - openPR
Hologic Inc Stock (HOLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):